Aquinnah Pharmaceuticals is a National Institute of Neurological Disorders and Stroke
Aquinnah Pharmaceuticals is focused on an exciting new area of research and development to modulate neurodegenerative stress granules, believed to be important in the pathology of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 17, 2019 | Grant | $750K | 2 | Alzheimer's Association | — | Detail |
Jun 21, 2018 | Grant | $3.40M | 1 | National Institutes of Health | — | Detail |
Apr 25, 2017 | Series Unknown | $10M | 2 | Pfizer AbbVie | — | Detail |
Dec 21, 2015 | Series Unknown | $5M | 1 | Takeda | — | Detail |
Nov 23, 2015 | Grant | $680K | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Alzheimer's Association | Yes | Grant |
National Institutes of Health | Yes | Grant |
Pfizer | Yes | Series Unknown |
AbbVie | Yes | Series Unknown |
Takeda | Yes | Series Unknown |
Tau Consortium | — | Grant |